| Recruiting | Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or NCT07387471 | AbbVie | Phase 2 |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Recruiting | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macrog NCT06986174 | Shayna Sarosiek, MD | Phase 2 |
| Recruiting | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lympho NCT07231952 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Enrolling By Invitation | Watch and Wait or Worry and Wait in Indolent Lymphoma NCT07173790 | Seoul National University Hospital | — |
| Recruiting | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | 64Cu-LLP2A for Imaging Hematologic Malignancies NCT06636175 | Washington University School of Medicine | EARLY_Phase 1 |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691 | Hutchmed | Phase 1 |
| Recruiting | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Ritu NCT04840602 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent NCT04883437 | Emory University | Phase 2 |
| Suspended | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diag NCT04799275 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Completed | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies NCT04279405 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders NCT03601819 | University of Michigan Rogel Cancer Center | Phase 1 |
| Active Not Recruiting | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgki NCT03884998 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade NCT03410901 | Ronald Levy | Phase 1 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Completed | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221 | University of Maryland, Baltimore | Phase 2 |
| Completed | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL NCT03019666 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Active Not Recruiting | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom NCT02952508 | Cellectar Biosciences, Inc. | Phase 2 |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Unknown | Study of VTD in Waldenstrom's Macroglobulinemia NCT03335098 | Seoul National University Hospital | Phase 2 |
| Active Not Recruiting | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma NCT02339922 | University of Washington | Phase 2 |
| Completed | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715 | Mayo Clinic | N/A |
| Active Not Recruiting | Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma NCT01209871 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies NCT01163201 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Imexon for Relapsed Follicular and Aggressive Lymphomas NCT01314014 | University of Rochester | Phase 2 |
| Completed | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas NCT01282424 | Gilead Sciences | Phase 2 |
| Completed | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma NCT00644189 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Recruiting | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic NCT00923507 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. NCT00801281 | Polish Lymphoma Research Group | Phase 3 |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia NCT00142129 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia NCT00142116 | Steven P. Treon, MD, PhD | Phase 2 |
| Completed | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia NCT00142181 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia NCT00566332 | French Study Group on Chronic Lymphoid Leukemia | Phase 3 |